Buyerdock is a Software as a Service (SAAS) global discovery platform that allows retail buyers instant access to compliant ready brands through the company's intelligent cloud technology. Buyerdock enables each supplier to upload details like product information, barcodes, images, and pack size on the portal. Retail buyers can then scrutinise all the available information within specific product categories and select the inventory they wish to purchase intuitively. Buyerdock received a mention from the former CEO of Sainsbury's that the former will speed up the buying process from 6 months to under 3 for retail buyers. The company is in talks with the top six UK retailers, such as Tesco, Marks & Spencer, Home Retail Group, Sainsbury's, Asda, and Morrisons. It will use the investment to grow its business and target the approximate 306,000 retail outlets in the UK, of which around 200,000 are independent retailers.
days to go:
Expired
investment:
£121,157
Liquid supplements are a faster acting and a more efficient way for the body to absorb key active ingredients than taking pills. Our scientists have developed formulations involving leading active ingredients such as collagen in order to create the perfect wellness solution in every bottle. Each LQ bottle is packed full of 9 or more active ingredients all in one easy to drink, daily 50 m bottle.
days to go:
Expired
investment:
£355,000
Zap and Go have created ultra fast technology for cordless and hand held devices by using Carbon-Ion technology which result in ultra-fast charging, taking 5 minutes or less. The technology is part derived from Oxford University and in part developed independently by Zap&Go's own scientists.
days to go:
Expired
investment:
£1,353,551
VoxSmart is a global mobile technology company focused on achieving compliance in a very heavy regulated industries such as finance and banking. VoxSmart software is embedded on the mobile device and allows the capturing and recording of all communications on that device
days to go:
Expired
investment:
£3,857,500
Kaleao has created simple, agile and flexible hardware and software systems which provide 10x more performance per unit of space and consumes 4x less energy. They maintain all promises of the hyperconvergence through the convergence of compute, storage and networking hardware whilst teamed with a full-featured and flexible software platform.
days to go:
Expired
investment:
£2,050,000
Publisher Discovery, using AI & Machine Learning technologies, provides recommendations to Advertisers of highly relevant Publishers in the affiliate marketing sector. The company has built a uniquely curated database of over 2 million publishers and 330,000 advertisers, which are then analysed, compared, and matched to make recommendations in ranked lists, matching the best publishers with each advertiser. The affiliate publishing market is worth 16 billion dollars per year but is still largely dominated by human-based agencies and is uniquely suited for automation. Publisher Discovery aims to capitalise on this aspect and establish itself as the market leader. The company has signed up over 50 publishers and is negotiating contracts with two large distribution partners. It is currently raising £1 million investment with £675,000 committed so far, to grow sales and operations and reach over £2m Annual Recurring Revenue (ARR) in the following 12 months.
days to go:
Expired
investment:
£800,000
Qure are an affordable and convenient on-demand healthcare service providing a doctor to users doors within 2 hours, 24/7. The hassle-free healthcare connects individuals with highly-experienced medical practitioners in the local area.
days to go:
Expired
investment:
£720,000
The Face Recognition Company (FRC) produces 90%+ accurate face recognition solution. In 2016, the company came up with the objective to develop the most accurate and cost-effective facial recognition solution. This technology is suitable for commercial applications or crime and other security uses. Additionally, the FRC's go-to-market strategy incorporates working through large integrators/partners/approved installers, eight of which are ready to promote and install its product to their own customer base. The FRC team has technically developed this solution by combining 100 years of experience in facial recognition. In June 2018, FRC had filed for two patents: first, ‘Recognition of 3D Objects’ and second, 'Method of and System for Recognising a Human Face’. Where suitable, FRC has also set-up an EIS tax relief.
days to go:
Expired
investment:
£215,600
Intelligent Health aim to get the whole community active by providing games and incentives such as ''beat the street''. By providing schools and communities with friendly competition to walk and cycle more by tapping their cards on ''beat boxes'', and with prizes and league tables on offer, Intelligent health are bringing communities together.
days to go:
Expired
investment:
£700,000
Ceryx Medical is a medical technological entity that is developing bioelectronics based on a unique, patent-protected, chip technology that can mimic nerve centres within the body called Central Pattern Generators (CPGs). CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate, and even walking. The Ceryx system resembles a traditional cardiac pacing device that holds a lot of promise in potentially alleviating incidences of heart failure leading to a therapeutic effect on patient health. In the UK, this is a day surgery procedure under local anaesthetic with a basic system costing around £3500. The device, therefore, offers a cost-effective, single procedure solution for this currently intractable disease. Treatment expenditures on heart failure cases in the EU amount to almost £35 billion. The Ceryx system is a potential disruptor in this segment and offers multiple potential applications. The company is targeting £500,000 as part of £1 million round. With the investment, the company aims to produce a data package that mimics those used to support 510k/NDA applications, as mandated by the US Food and Drug Administration (FDA), for current devices and drugs used to treat heart failure.
days to go:
Expired
investment:
Withheld
